Core One Labs Stock Price, News & Analysis

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF) has entered a definitive agreement to acquire Ketamine Infusion Centers of Texas Inc. (KICT), marking its first health and wellness operation in the US. The acquisition is aimed at addressing depression and mental health issues through psychedelic-assisted psychotherapy using psilocybin, pending legalization. KICT offers Ketamine treatments for various mental health disorders. The US psychedelic drug market is projected to grow significantly, reaching approximately $6.8 billion by 2027, highlighting the strategic importance of this acquisition.

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF) recently held an International Investors' Call featuring updates on its Intellectual Property and psilocybin production. The Company is preparing to file its first patent application for biosynthetic psilocybin production, using engineered bacteria to reduce production costs significantly. Current synthesis methods range from $7,000 to $10,000 per gram, while Core One aims to produce it at one-hundredth of that cost. CEO Joel Shacker expressed confidence in their market position and plans for future updates.

Core One Labs Inc. (CSE:COOL)(OTC Pink:CLABF) announced plans to file a patent application for its proprietary biosynthetic psilocybin production system. Following initial research, the company has gathered data to initiate its first filing with the USPTO, part of a series aimed at protecting intellectual property. Core One's team continues to refine its DNA expression system to enhance psilocybin production. CEO Joel Shacker emphasized that these patents are crucial for safeguarding development efforts and creating shareholder value.

Core One Labs Inc. (OTC PINK: CLABF) announced enhanced teleconference capabilities for its scheduled call on February 10, 2021, featuring updates from Chairman Dr. Robert E.W. Hancock and CEO Joel Shacker. The discussion will focus on the company’s progress and differentiators within the psychedelic space. Core One Labs is engaged in developing psychedelic medicines through innovative delivery systems, including a patent-pending thin film oral strip for precise dosing. The firm aims to advance regulatory approval for psychedelic treatments targeting mental health disorders.

Core One Labs Inc. has engaged Donohoe Advisory Associates to assist in seeking a NASDAQ listing, aiming to enhance investor awareness and market liquidity. The advisory firm, led by experienced professionals from NASDAQ and NYSE, has a strong track record in listings. As interest in the psychedelics market rises, driven by notable investors and companies, the timing appears favorable. Core One Labs plans to host a conference call on February 10, 2021, to discuss its strategy and recent developments in the psychedelic space. However, a listing is subject to regulatory approvals and other requirements.

Core One Labs Inc. (OTC PINK:CLABF) has entered a letter of intent to acquire Ketamine Infusion Centers of Texas (KICT) for US$200,000, to be paid in shares. KICT specializes in treating treatment-resistant depression and other mental health disorders through ketamine infusion therapies. This acquisition is part of Core One's strategy to expand its foothold in the psychedelic medicine market. With this move, Core One aims to leverage KICT's established protocols and patient base, enhancing its research capabilities in psychedelic treatments.

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF) announced a Letter of Intent with High Tower Capital Inc. to sell certain assets for CAD$3,000,000 and the assumption of USD$4,015,885 in liabilities. This strategic move allows Core One to focus on its psychedelic innovations and further develop its CannaStrip™ technology. The sale is aimed at reducing monthly capital outlays and reallocating resources towards expanding the psychedelic sector. Completion is contingent upon due diligence and regulatory approvals.